A review published on Current Opinion in Pulmonary Medicine on July 8, 2025 examines recent negative clinical trials in pulmonary arterial hypertension (PAH) research, emphasizing the valuable insights these studies provide despite their unsuccessful outcomes.
The article reviews several recent negative trials testing various therapeutic approaches in pulmonary arterial hypertension, including tocilizumab (an anti-inflammatory drug), selonsertib (a kinase inhibitor), rodatristat ethyl (a tryptophan hydroxylase inhibitor), anastrazole (an aromatase inhibitor), and AV-101 (dry powder inhaled imatinib).
The authors stress the critical value of publishing all clinical trial results, regardless of outcome. Negative studies help the medical community avoid repeating unsuccessful approaches, better understand disease complexity, and prioritize more promising therapeutic targets and treatment pathways for future research. This comprehensive approach to sharing both positive and negative results ultimately accelerates progress in pulmonary arterial hypertension research and improves the chances of developing effective treatments for patients.
Citation
Cullivan S, McCourt L, Gaine S. Important negative trials in pulmonary hypertension. Curr Opin Pulm Med. 2025 Jul 8. doi: 10.1097/MCP.0000000000001198. Epub ahead of print. PMID: 40620169.
Read more at this link on the NIH National Library of Medicine
